Stocks in the Spotlight Monday

Amylin, Pep Boys, Thomas & Betts and US Airways all rose.

Shares gained 17% on news that the Food and Drug Administration approved Amylin's once-weekly Bydureon for diabetes. MKM Partners analyst Jon LeCroy reiterated a Sell rating on Amylin but raised the price target to $10.50 from $8.50. "In our view, generating a robust launch for Bydureon could be a major...